Skip to Main Content

INFORMATION FOR

Darryl Martin, PhD

Assistant Professor

Contact Information

Darryl Martin, PhD

Research Summary

Dr. Martin’s interest encompasses both translational and biomedical research. His current research focuses on understanding the mechanisms involved in chemotherapeutic resistant bladder tumors as well as identifying the molecular signatures of heterogeneous prostate cancers. Dr. Martin uses patient derived tumors, primary cancer cells and cancer mouse models to develop novel therapies. He is currently funded by the Department of Defense to study tumor-homing nanoparticles for the imaging and treatment of prostate cancer.

Extensive Research Description

  • Project 1 attempts to understand the mechanism(s) involved in chemotherapeutic resistant bladder tumors
  • Project 2 aims to identify the molecular signatures of heterogeneous prostate cancers
  • Project 3 uses functionalized nanoparticles to locate and treat prostate cancer

Resistant bladder tumors; Heterogeneous prostate cancers; Tumor-homing nanoparticles

Coauthors

Research Interests

Urinary Bladder Neoplasms; Inflammation; Prostatic Neoplasms; Drug Delivery Systems; Cystitis, Interstitial; Biomedical Research; Nanomedicine; Translational Research, Biomedical; Tumor Microenvironment

Selected Publications

  • MP49-10 KNOCKDOWN OF GLYCOPROTEIN-130 INHIBITS BLADDER CANCER PROGRESSION AND MIGRATIONMartin D, Steinbach J, Wheeler M, Nawaf C, Saltzman W, Weiss R. MP49-10 KNOCKDOWN OF GLYCOPROTEIN-130 INHIBITS BLADDER CANCER PROGRESSION AND MIGRATION Investigative Urology 2015, 193: e606. DOI: 10.1016/j.juro.2015.02.514.
  • Blocking Glycoprotein‐130 Pathway Decreases Bladder Cancer GrowthMartin D, Steinbach J, Saltzman W, Weiss R. Blocking Glycoprotein‐130 Pathway Decreases Bladder Cancer Growth The FASEB Journal 2015, 29 DOI: 10.1096/fasebj.29.1_supplement.889.11.
  • A novel polymer-coated nanoparticle (NP) for urothelium penetration and drug delivery.Hoimes C, Martin D, Kaimakliotis H, Cheng C, Kelly W, Tew G, Wheeler M, Weiss R, Saltzman W. A novel polymer-coated nanoparticle (NP) for urothelium penetration and drug delivery. Journal Of Clinical Oncology 2013, 31: e15543-e15543. DOI: 10.1200/jco.2013.31.15_suppl.e15543.
  • MP-04.16 Uptake of Surface Modified Poly(Lactide-Co-Glycolide) Nanoparticles in Bladder Cancer Cells and in Human Ureter and Mouse BladderWeiss R, Martin D, Steinbach J, Liu J, Kaimakliotis H, Wheeler M, Hittelman A, Saltzman W. MP-04.16 Uptake of Surface Modified Poly(Lactide-Co-Glycolide) Nanoparticles in Bladder Cancer Cells and in Human Ureter and Mouse Bladder Urology 2011, 78: s55. DOI: 10.1016/j.urology.2011.07.090.
  • 1055 SURFACE MODIFICATIONS OF POLY(LACTIDE-CO-GLYCOLIDE) NANOPARTICLES CAN INCREASE ITS UPTAKE BY BLADDER CANCER CELLSMartin D, Steinbach J, Kaimakliotis H, Liu J, Wheeler M, Hittelman A, Saltzman W, Weiss R. 1055 SURFACE MODIFICATIONS OF POLY(LACTIDE-CO-GLYCOLIDE) NANOPARTICLES CAN INCREASE ITS UPTAKE BY BLADDER CANCER CELLS Investigative Urology 2011, 185: e424. DOI: 10.1016/j.juro.2011.02.1092.
  • 1358 NANOPARTICLE DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR PXD101 FACILITATES BLADDER CANCER CELL UPTAKE AND CYTOTOXICITYKaimakliotis H, Martin D, Hoimes C, Cheng C, Liu J, Kelly K, Tew G, Saltzman W, Weiss R. 1358 NANOPARTICLE DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR PXD101 FACILITATES BLADDER CANCER CELL UPTAKE AND CYTOTOXICITY Investigative Urology 2011, 185: e542. DOI: 10.1016/j.juro.2011.02.1180.